Navigation Links
Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
Date:3/3/2008

- HspE7 Well Tolerated; Fourth Cohort to be Dosed Shortly -

SAN DIEGO, March 3 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation (TSX: NVN) today announced the completion of the safety and tolerability assessment of its third cohort of patients in a Phase 1 clinical trial of new HspE7 (HspE7 + Poly-ICLC) in patients with cervical intraepithelial neoplasia (CIN). The safety data from the cohort were normal and met the limits prescribed in the trial protocol, allowing advancement to the fourth cohort of patients in the study.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080303/LAM023LOGO)

The evaluation by the Safety Review Committee was performed after the third cohort reached five weeks of treatment (two doses plus one week of follow-up). The dosing of the fourth cohort of patients is expected shortly.

At the end of each cohort, Nventa is also collecting immunological data that may provide an early indication of potential efficacy of the compound. All patients are being typed for class I and II human leukocyte antigen (HLA) subtypes, and are being evaluated for cytokine responses, anti-HspE7 antibodies and cellular (T-cell) immunology.

The trial is expected to dose up to 5 cohorts comprising twenty-four patients. The first cohort of patients was administered 500 mcg of HspE7 and 50 mcg of adjuvant containing Poly-IC, a toll-like receptor-3 (or TLR3) agonist. The second cohort was administered 500 mcg of HspE7 and an escalated dose of 500 mcg of adjuvant. The third cohort was administered 500 mcg of HspE7 and 1,000 mcg of adjuvant. The fourth cohort will be administered 500 mcg of HspE7 and 2,000 mcg of adjuvant. An additional cohort of patients administered 1,000 mcg of HspE7 and 2,000 mcg of adjuvant may be added if deemed appropriate based on data from the previous four cohorts.

Following successful completion of th
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
7. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
8. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
9. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
10. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
11. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... -- Report Details   Translational ... progress, and predicted revenues ,Where is the market for ... prospects for this market and related technologies? Visiongain,s brand ... to 2025, discussing data, opportunities and prospects. ... medicine : cell-based therapies that aim to restore function ...
(Date:2/27/2015)... OF PRUSSIA, Pa. , Feb. 27, 2015 /PRNewswire/ ... of its ongoing commitment to the global bleeding disorders ... is donating 2 million international units (IUs) of protein ... is an international not-for- profit organization which has worked ... other inherited bleeding disorders. The donation supports the WFH,s ...
(Date:2/27/2015)...  PTC Therapeutics, Inc. (NASDAQ: PTCT ) ... for the fourth quarter and full year ended December ... year for PTC. We are now a growing commercial-stage ... in the rare disease space," stated Stuart W. Peltz, ... proud to bring the first treatment for Duchenne muscular ...
Breaking Medicine Technology:Translational Regenerative Medicine: Market Prospects 2015-2025 2Translational Regenerative Medicine: Market Prospects 2015-2025 3Translational Regenerative Medicine: Market Prospects 2015-2025 4Translational Regenerative Medicine: Market Prospects 2015-2025 5Translational Regenerative Medicine: Market Prospects 2015-2025 6Translational Regenerative Medicine: Market Prospects 2015-2025 7Translational Regenerative Medicine: Market Prospects 2015-2025 8CSL Behring Continues Treatment Access Leadership by Donating Bleeding Disorder Protein Therapies IUs to World Federation of Hemophilia 2CSL Behring Continues Treatment Access Leadership by Donating Bleeding Disorder Protein Therapies IUs to World Federation of Hemophilia 3PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 10PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 11
(Date:3/1/2015)... New York (PRWEB) March 01, 2015 ... hip lawsuit (( http://www.consumerinjurylawyers.com/wright-profemur-hip-replacement ) scheduled to go ... defense must prepare a witness to provide testimony ... in the development of the Profemur device, Bernstein ... in U.S. District Court, Northern District of Iowa ...
(Date:3/1/2015)... “ The Barrel Mill ” was featured ... takes a look at the latest and coolest technology products ... NewsWatch and a technology expert, conducted the review and shared ... drinks. , According to Home Distillation of Alcohol, it's understood ... there’s a pretty cool product that’ll help anyone achieve a ...
(Date:2/28/2015)... March 01, 2015 Heart diseases are ... 10 percent of urban adult population and 5 percent ... heart diseases and 20-30 percent of them require specialized ... ailments and coronary vascular diseases (CVD). , A division ... new market research report titled “Indian Coronary Stent Market ...
(Date:2/28/2015)... Portland, Oregon (PRWEB) February 28, 2015 ... Portland, Oregon, is offering a new special. Throughout ... denture relines. , This service ... from sleep problems and pain. Patients may notice certain ... and need relining. These symptoms include: , 1.    Pain, ...
(Date:2/28/2015)... Carlsbad, CA (PRWEB) February 28, 2015 ... developed a promising new gene therapy procedure for the ... progressive blindness in patients. Authored by Dr. ... Oxford and published in the Lancet Medical Journal on ... suffering from choroideremia, a rare genetic disorder that mostly ...
Breaking Medicine News(10 mins):Health News:Wright Profemur Hip Lawyers at Bernstein Liebhard LLP Comment on Court’s Decision Regarding Testimony Pertaining to Prototype for Profemur Hip Replacement 2Health News:Wright Profemur Hip Lawyers at Bernstein Liebhard LLP Comment on Court’s Decision Regarding Testimony Pertaining to Prototype for Profemur Hip Replacement 3Health News:An Oak Infusion Spiral was Featured on NewsWatch Television on January 30, 2015 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 3Health News:Classic Denture Center in Portland Oregon is Offering March Discount 2Health News:New Gene Therapy Procedure Could Hold Key to Preventing Blindness for Certain Patients 2
... antioxidants may protect people like athletes, soldiers from fatal temperature ... key to curing heat stroke may have been found in ... suffer a deadly rise in body temperature, according to a ... April 4 issue of Cell , also suggest that ...
... Patients with genital and nipple piercings, also known as ... positive discussions about them, according to a new article in ... too often, such discussions do not occur, even when treating ... healthcare providers uneasiness over this increasingly common form of body ...
... Care Net,President Melinda Delahoyde spoke out Thursday about the ... that,these two young girls felt that secretly disposing of ... Delahoyde. "We are saddened they,didn,t receive help from one ... Houston to offer hope and assistance to people like ...
... a Convenient Chewable ... Tablet, ... weather also brings the onslaught of insects and,parasites, including fleas. For many ... oral flea protection product from,Eli Lilly and Company, protecting your dog from ...
... health care information to,patients for disease management, case ... Today URAC called,for public comment on revisions to ... programs. URAC is seeking input from any,interested parties, ... and health plans. The deadline for public,comment is ...
... Caves reveal genetic material in excrement linking New World ... News) -- The oldest human DNA ever found in ... or East Asia, according to an international team of ... on maternally) was discovered in 14,300-year-old dried human excrement, ...
Cached Medicine News:Health News:Genetic Disorder May Hold Key to Heat Stroke Cure 2Health News:Genetic Disorder May Hold Key to Heat Stroke Cure 3Health News:Tragedies Point to Need for Pregnancy Centers, Care Net Says 2Health News:Spring Weather Brings Flea Season 2Health News:Spring Weather Brings Flea Season 3Health News:URAC Releases Draft Standards for Public Input for Nine Health Care Management Accreditation Programs 2Health News:DNA Find in Oregon Is Oldest Yet Discovered in Americas 2
Test for prostatic acid phosphatase...
For the quantitative measurement of human prostatic acid phosphatase (PAP) in human serum....
... a Windows 2000 PC based EEG with ... and software. EEG-9200 provides high quality performance ... in the sleep lab or EEG lab. ... the electrically noisy OR or ICU. Neurofax ...
... the first magnetic stimulator to offer the ... It is designed to provide the simplest ... routine (at the same time, it may ... can control operations without moving away from ...
Medicine Products: